Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial

Canagliflozin is a sodium –glucose cotransporter 2 inhibitor that has been shown to reduce cardiovascular events in diabetic patients with and without heart failure (HF). Whether the clinical benefits and safety profile of canagliflozin are different in those on a beta blocker and an angiotensin-converting enzyme inhibitor /angiotensin receptor blocker (BB + RAASi) is unknown.

Source: International Journal of Cardiology - October 14, 2023 Category: Cardiology Authors: Sneha S. Jain, Jie Yu, Clare Arnott, Bruce Neal, Vlado Perkovic, Brendon L. Neuen, Meg Jardine, Kenneth W. Mahaffey Tags: Short communication Source Type: research